- Home
- PRTA vs KIO Comparison
PRTA vs KIO Comparison
Compare PRTA & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- KIO
- Stock Information
- Founded
- PRTA 2012
- KIO 2011
- Country
- PRTA Ireland
- KIO United States
- Employees
- PRTA N/A
- KIO 2400
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- PRTA Health Care
- KIO Finance
- Exchange
- PRTA Nasdaq
- KIO Nasdaq
- Market Cap
- PRTA 472.1M
- KIO 522.7M
- IPO Year
- PRTA N/A
- KIO N/A
- Fundamental
- Price
- PRTA $9.92
- KIO $11.70
- Analyst Decision
- PRTA Buy
- KIO
- Analyst Count
- PRTA 9
- KIO 0
- Target Price
- PRTA $13.14
- KIO N/A
- AVG Volume (30 Days)
- PRTA 785.0K
- KIO 136.5K
- Earning Date
- PRTA 11-11-2025
- KIO 01-01-0001
- Dividend Yield
- PRTA N/A
- KIO 10.82%
- EPS Growth
- PRTA N/A
- KIO N/A
- EPS
- PRTA N/A
- KIO N/A
- Revenue
- PRTA $10,341,000.00
- KIO N/A
- Revenue This Year
- PRTA N/A
- KIO N/A
- Revenue Next Year
- PRTA $602.32
- KIO N/A
- P/E Ratio
- PRTA N/A
- KIO N/A
- Revenue Growth
- PRTA N/A
- KIO N/A
- 52 Week Low
- PRTA $4.32
- KIO $10.52
- 52 Week High
- PRTA $18.88
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- PRTA 55.31
- KIO 17.71
- Support Level
- PRTA $9.98
- KIO $11.93
- Resistance Level
- PRTA $10.90
- KIO $12.50
- Average True Range (ATR)
- PRTA 0.47
- KIO 0.16
- MACD
- PRTA -0.06
- KIO -0.08
- Stochastic Oscillator
- PRTA 23.93
- KIO 8.39
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.